Last reviewed · How we verify
Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
Approved treatments
- Darzalex Faspro · Pfizer
Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy patent landscape — cliff calendar, originator estates, attackable patents
- Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy treatment landscape brief
- Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy treatment updates RSS
Frequently asked questions about Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
What drugs treat Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy?
Tracked treatments include Darzalex Faspro.
What is the treatment for Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy?
Standard treatment for Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy includes Darzalex Faspro. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy patent cliff · Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy CI report
- Treatment: Darzalex Faspro · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing